業績

当教室関連研究の論文

国内外の多く研究機関との共同研究、ならびに多施設共同研究グループへの参加を積極的に行っています。

2025

Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators: Rose H, Chong G, Ganju V, Chu M, Keating MM, Song Y, Zhu J, Ke X, Yi S, Zhang H, Zhang Q, Zou L, Zhang M, Li D, Qian W, Bai O, Gao L, Jin J, Li C, Huang H, Wei Z, Chen Y, He P, Damaj LG, Bouabdballah K, Bachy E, Haioun C, Morschhauser F, Choquet S, Delwail V, Thieblemont C, Duell J, Weber T, La Rosee PG, Hebart H, Capochiani E, Zilioli V, Rossi F, Luminari S, Zinzani PL, Bagnato L, Gaidano G, Brociner M, Skert C, Tani M, Battistini R, Flenghi L, Yamamoto R, Tsukasaki K, Ishizawa K, Tobai T, Uchida T, Minami Y, Yamauchi N, Yuda J, Takeuchi M, Nagai H, Suehiro Y, Ogawa Y, Kuroda J, Jo T, Nakamae H, Yoshida I, Taszner M, Lech-Maranda E, Knopinska-Posluszny W, Wrobel T, Robak T, Hsieh WS, Ong SY, Eom HS, Mun YS, Do YR, Kim JS, Kim BS, Jo JC, Jimenez-Ubieto A, Andreu R, Martin A, Coello AP, Cordoba R, Alonso A, Magnano L, Gonzalez-Barca E, Miqueleiz S, Chen TY, Yeh SP, Wu SJ, Wang MC, Cunningham D, Kuhnl A, Tucker D, Lewis D, Elmusharaf N, Allan J, Jandl T, Ibrahimi S, Jagadeesh D, Leslie L, Venugopal P, Arnason J, Villasboas JC, Vaidya R, Stevens D, Awan F, Klein A, Farooq U. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025, in print/（多施設共同研究）

Onishi A, Miyagawa-Hayashino A, Okamoto H, Fujino T, Tuskamoto T, Mizutani S, Shimura Y, Konishi E, Kuroda J. Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma. Leuk Lymphoma, in print.

Fujino T, Okamoto H, Nishiyama D, Hayata H, Sasaki N, Kobayashi T, Maekura C, Kuwahara-Ota S, Takimoto-Shimomura T, Shimura K, Kawaji-Kanayama Y, Inoue Y, Chinen S, Isa R, Tsukamoto T, Mizutani S, Shimura Y, Kaneko H, Nakao M, Fuchida S, Takahashi R, Uchiyama H, Uoshima N, Kuroda J, Kyoto Clinical Hematology Study Group. Real-world data of Polatuzumab Vedotin with Bendamustine and Rituximab for Japanese relapsed and refractory DLBCL： A Multicenter Retrospective Study. Leuk Lymphoma, in print.（KOTOSG研究）

Fukuhara N, Yoshida I, Ishiguro T, Fujimoto K, Kuroda J, Uchida T, Yamamoto R, Ogawa Y, Hiramatsu Y, Ito T, Katagiri S, Nakazato T, Suzukawa K, Kinami K, Zhou M, Negoro E. PI3Kδ inhibitor parsaclisib in Japanese patients with relapsed or refractory follicular lymphoma. Cancer Sci, in print.（多施設共同研究）

Makishima H, Mikasa T, Isogaya K, Miyamoto T, Yamauchi T, Yokota A, Onozawa M, Ando K, Ogawa Y, Usuki K, Yamauchi T, Ota S, Takada S, Morita Y, Ishikawa T, Takenaka K, Kuroda J, Sekiguchi N, Kawakita T, Miyazaki Y. Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351. Int J Hematol. 2025, in print.（多施設共同研究）

Iyama S, Chi S, Idogawa M, Ikezoe T, Fukushima K, Utsu, Kanda J, Yoshimoto G, Kobayashi T, Hosono N, Yamauchi T, Kondo T, Nakamura Y, Kojima K, Yoshida, Gotoh A, Yamamoto K, Kuroda J, Ishitsuka K, Sakaida E, Horiguchi H, Takada K, Ohnishi H, Kobune M, Minami Y, all HM-SCREEN-Japan 01/02 investigators. Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN- Japan 01 and 02 study. Ann Hematol, in print.（多施設共同研究）

Nagata H, Tsukamoto T, Kobayashi T, Takahashi R, Okano A, Uchiyama H, Kawata E, Uoshima N, Kaneko H, Fuchida S, Nishiyama D, Nakao M, Fujino T, Mizutani S, Shimura Y, Kuroda J. The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma. Int J Clin Oncol, in print.（KOTOSG研究）

Ri M, Iida S, Saito K, Saito Y, Maruyama D, Asano A, Fukuhara S, Tsujimura H, Miyazaki K, Ota S, Fukuhara N, Negoro E, Kuroda J, Yoshida S, Otsuka E, Tsukamoto N, Tabayashi T, Takayama N, Saito T, Suzuki Y, Harada Y, Mizuno I, Yoshida I, Maruta M, Takamatsu Y, Katsuya H, Yoshimitsu M, Minami Y, Kanato K, Munakata W, Nagai H. Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105. Cancer Chemother Pharmacol, 95(1): 29, 2025.（多施設共同研究）

Inoue Y, Tsukamoto T, Mizuhara K, Maekura C, Nakamura T, Okamoto H, Fujino T, Mizutani S, Shimura S, Maruyama A, Nakanishi M, Tanaka F, Nishida Y, Ishii K, Sonobe Y, Miyagawa-Hayashino A, Kuroda J. Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma complicated by paraneoplastic encephalitis. Intern Med, in print.

Okamoto H, Mizutani S, Tsukamoto T, Katsuragawa-Taminishi Y, Kawaji-Kanayama Y, Mizuhara K, Muramatsu A, Isa R, Fujino T, Shimura Y, Ichikawa K, Kuroda J. Robust Anti-myeloma Effect of TAS0612, an RSK/AKT/S6K Inhibitor, with Venetoclax Regardless of Cytogenetic Abnormalities. Leukemia 39(1): 211-221, 2025.

Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. Int J Hematol 120(5); 621-630, 2024.（多施設共同研究）

河田英里, 藤野貴大,古林　勉、岡本明也,塚本　拓, 水谷信介, 志村勇司, 西山大地、上辻由里、淵田真一、中尾光成、高橋良一、兼子裕人、内山人二、平川浩一、魚嶋伸彦、黒田純也. 京都血液臨床研究グループ(KOTOSG)による15年間の臨床研究に基づくびまん性大細胞型B細胞リンパ腫の診療課題と展望. 臨床血液 66(3):153-164, 2025.

2024

Shimazu Y, Kanda J, Takakuwa T, Onda Y, Fukushima K, Hotta M, Fuchida S, Uoshima N, Shimura Y, tanaka K, Ohta K, Shibayama H, Kosugi S, Yagi H, Yoshihara S, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. The Impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients. Ann Hematol 103(12); 5639-5649, 2024（多施設共同研究）

Niiyama-Uchibori Y, Mizutani S, Tsukamoto T, Okamoto H, Ide D, Onishi A, Kato D, Fujino T, Shimira Y, Miyagawa-Hayashino A, Konishi E, Karube K, Nannya Y, Kuroda J. Small cell pattern of ALK-negative anaplastic large cell lymphoma with double hit rearrangements of DUSP22 and TP63. eJHaem 5(4): 798-801, 2024.

Shishido-Hara Y, Miyagawa-Hayashino A, Kuroda J. B-cell maturation in angioimmunoblastic T cell lymphoma (AITL): Development of secondary diffuse large B cell lymphoma (DLBCL) is likely associated with Attygalle patterns II and III. Medical Research Archives 12(9), 2024.

Shishido-Hara Y, Iguchi R, Kuroda J. An autopsy case of EBV-positive CD8+ T cell lymphoma after allogeneic transplantation of peripheral blood stem cells. Medical Research Archives 12(9), 2024.

Harada Y, Makino M, Nakao R, Shimura Y, Ogata T, Hayakawa M, Shiraishi H, Kuroda J, Matoba S, Tanaka H. An Autopsy Case of Severe COVID-19 Pneumonia Complicated by Intrapulmonary Thrombosis in Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis. Cureus 16(6): e62790, 2024.

Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Final analysis of phase IIb results. Haematologica, 109(10): 3357-3362, 2024.（多施設共同研究）

Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer Immunol Immunother. 73:135, 2024.（多施設共同研究）

Hashiro W, Miyashita A, Kawaji-Kanayama Y, Okamoto H, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kuroda J. Good’s Syndrome With Pure Red Cell Aplasia and Subclinical Myasthenia Gravis: A Case Report and Review of Literature. Cureus, 16（5）：e59654, 2024.

Yamamoto C, Taniguchi M, Furukawa K, Inaba T, Niiyama Y, Ide D, Mizutani S, Kuroda J, Tanino Y, Nishioka K, Watanabe Y, Takayama K, Nakaya T, Nukui Y. Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019. Viruses, 16(5):718, 2024.

Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, Ota S, Yoshimitsu M, Tanaka Y, Kurahashi S, Fuchida SI, Iino M, Shimizu T, Moriuchi Y, Toyama K, Mitani K, Tsukune Y, Kada A, Tamura H, Abe M, Iwasaki H, Kuroda J, Takamatsu H, Sunami K, Kizaki M, Ishida T, Saito T, Matsumura I, Akashi K, Iida S. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021). Int J Hematol. 119: 707-721, 2024.（多施設共同研究）

Watanabe T, Matsuno Y, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Tsukasaki K, Tobinai K, Nagai H. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203. Hematol Oncol, 42: e3272, 2024.（多施設共同研究）

Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, Kuroda J, Sunami K, Kamimura T, Ogawa R, Kikushige Y, Harada M, Akashi K, Miyamoto,T. Autologous HSCT with Novel Agent-Based Induction Followed by Lenalidomide Maintenance for Untreated Multiple Myeloma. Cancer Sci, 115: 2002-2011, 2024.（多施設共同研究）

Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida S, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Ann Hematol, in print.（多施設共同研究）

Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K. ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood, 143: 2401-2413, 2024.（多施設共同研究）

Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, Isa R, Tsukamoto T, Mizutani S, Uchiyama H, Kaneko H, Uoshima N, Kawata E, Taniwaki M, Shimura Y, Kuroda J, and Kyoto Clinical Hematology Study Group. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B cell lymphoma utilizing the lymphocyte-to-monocyte ratio. Int J Hematol, 119: 697-706, 2024.（KOTOSG研究）

Niiyama-Uchibori Y, Okamoto H, Miyashita A, Mizuhara K, Kanayama-Kawaji Y, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Teramukai S, Kuroda K. Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma. Hematol Oncol, 42:e3252, 2024.

Watanabe T, Tobinai K, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Matsuno Y, Tsukasaki K, Nagai H. Long-Term Safety and Efficacy of Advanced Follicular Lymphoma Patients Treated With Front-Line R-CHOP. Br J Haematol, in print. (多施設共同研究)

Kawaji-Kanayama Y, Tsukamoto T, Nakano M, Tokuda Y, Nagata H, Mizuhara K, Katsuragawa-Taminishi Y, Isa R, Fujino T, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Tashiro K, Kuroda J. miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma. Cancer Sci, 115:452-464, 2024.

Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, Miyashita A, Okumura K, Nishiyama D, Hirakawa K, Shimura K, Kaneko H, Kiyota M, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J, Kyoto Clinical Hematology Study Group investigators. Negative impact of immunoparesis in the response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma. Int J Hematol, 119: 50-61, 2024.（KOTOSG研究）

Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Ann Hematol, 103; 475-488, 2024. (多施設共同研究)

松本和道, 森教子, 田中千晴, 加藤萌香, 奥村敬太, 野村鮎美, 抱章子, 西村博志, 稲葉亨, 黒田純也. フローサイトメトリーでCD4 陰性芽球形質細胞様樹状細胞腫瘍と考えられた1 例. 日本検査血液学会雑誌第25(1), 28-35, 2024

前倉千佳, 大西朗生, 黒田純也. 血液疾患とCOVID-19. 京都府立医科大学雑誌133(12), 803-810, 2024

黒田純也, 岡本明也, 井上　祐. 多発性骨髄腫におけるゲノム分類と個別化治療の可能性. 血液内科、89;416-422, 2024

黒田純也. 未治療多発性骨髄腫に対する治療開発動向と展望. 血液内科88(4), 372-377, 2024

藤野貴大, 黒田純也. 濾胞性リンパ腫. 日本臨牀　別冊　血液症候群（第3版）IV、264-267, 2024

黒田純也. 形質細胞腫瘍. WHO分類第5版による白血病・リンパ系腫瘍の病態学. 中外医学社，493-512, 2024

塚本　拓, 黒田純也. 再発・難治多発性骨髄腫の治療方針. EBM血液疾患の治療 2025-2026. 中外医学社, 402-406, 2024

黒田純也. 未治療多発性骨髄腫に対する治療開発動向と展望. 血液内科. 印刷中.

2023

Takeuchi H, Inaba T, Shishido-Hara Y, Tsukamoto T, Mizutani S, Okamoto T, Tanigawa S, Yamanaka T, Takahashi Y, Konishi E, Kuroda J, Hashimoto N. Analysis of False-negative Findings of the Incomparable Accuracy and Swiftness of Flow Cytometric Diagnosis of Primary Central Nervous System Lymphoma. Neurol Med Chir (Tokyo), 63: 495-502, 2023（脳神経外科、臨床検査部との共同研究）

Nakaya A, Shibayama H, Uoshima N, Yamamura R, Yoshioka S, Imada K, Shimura Y, Hotta M, Matsui T, Kosugi S, Hanamoto H, Uchiyama H, Yoshihara S, Fuchida S, Onda Y, Tanaka Y, Ohta K, Matsuda M, Kanda J, Yoko A, Kiyota M, Kawata E, Takahashi R, Fukushima K, Tanaka H, Yagi H, Takakuwa T, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum. Leukemia Res Rep, 20, 100395, 2023. （多施設共同研究）

Katsuragawa-Taminishi Y, Mizutani S, Kawaji-Kanayama Y, Onishi A, Okamoto H, Isa R, Mizuhara K, Muramatsu A, Fujino T, Tsukamoto T, Shimura Y, Taniwaki M, Miyagawa-Hayashino A, Konishi E, Kuroda J. Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas. Cancer Sci, 114: 4691-4705, 2023

Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, Hanamoto H, Fuchida SI, Tanaka H, Kosugi S, Kiyota M, Matsui T, Kanda J, Iida M, Matsuda M, Uoshima N, Shibano M, Karasuno T, Hamada T, Ohta K, Ito T, Yagi H, Yoshihara S, Shimazaki C, Nomura S, Hino M, Takaori-Kondo A, Matsumura I, Kanakura Y, Kuroda J. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum. Int J Hematol. 118: 609-617, 2023. （多施設共同研究）

Inoue Y, Okamoto H, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida S, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J, and KOTOSG investigators. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: the Kyoto Conditional Survival Scoring System. Oncol Lett, 27:62, 2023.（KOTOSG研究）

Onishi A, Muramatsu A, Shimura Y, Murao T, Fujino T, Mizutani S, Tsukamoto T, Shishido-Hara Y, Kuroda J. Progressive Multifocal Leukoencephalopathy Initially Suspected As Brain Relapse From Classical Hodgkin’s Lymphoma. Cureus, 15: e44000, 2023.

Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Taminishi-Katsuragawa Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J. Tumor-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma. Br J Haematol, 203; 426-438, 2023.

Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida S, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J, and KOTOSG investigators. Real-World Practice-Based Prognostic Model for Higher-Risk Myelodysplastic Syndromes Treated with Azacitidine Monotherapy: the Kyoto Prognostic Scoring System. Int J Hematol, 118(3), 323-332, 2023.（KOTOSG研究）

Inoue Y, Fujino T, Chinen S, Niiyama-Uchibori Y, Ide D, Kawata M, Hashimoto K, Takimoto-Shimomura T, Nakayama A, Tsukamoto T, Mizutani S, Shimura Y, Hirano S, Kuroda J. Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Cureus, 15, e38905, 2023.

Kawajiri T, Takeuchi H, Takahashi Y, Shimura Y, Kuroda J, Hashimoto N. Biopsy-proven Primary CNS Lymphoma in the Medulla Oblongata Presenting as Anorexia. NMC Case Rep J, 10, 131-137, 2023.（脳神経外科との共同研究）

Uno S, Midorikawa S, Inoue K, Ichikawa D, Ito T, Kuroda J, Suzuki K. Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan. PLoS One, 18(5), e0295947, 2023

Shimazu Y, Kosugi S, Ito T, Kaneko H, Imada K, Shimura Y, Fuchida S, Fukushima K, Tanaka H, Yoshihara S, Ohta K, Uoshima N, Yagi H, Shibayama H, Yamamura R, Tanaka Y, Uchiyama H, Onda Y, Adachi Y, Hanamoto H, Takahashi R, Matsuda M, Miyoshi T, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or b2 microglobulin. Sci Rep, 13(1), 5159, 2023. （多施設共同研究）

Tsukamoto T, Kinoshita M, Yamada K, Ito H, Yamaguchi T, Chinen Y, Mizutani S, Fujino T, Kobayashi T, Shimura Y, Inazawa J, Kuroda J. Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. J Hum Genet, 114(5), 2098-2108, 2023. （東京医科歯科大学、シスメックス社、BML社との共同研究）

Potts MA, Mizutani S, Garnham AL, Li Wai Suen CSN, Kueh AJ, Tai L, Pal M, Strasser A, Herold MJ. Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis. Cell Death Differ. 2023 in print.(The Walter and Eliza Hall Institute of Medical Researchとの共同研究)

Souri M, Osaki T, Shimura Y, Ichikawa S, Mori M, Ogawa Y, Ichinose A. Identification of non-neutralizing anti-factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency. Haemophilia. 2023 Mar;29(2):555-563.（多施設共同研究）

Suzuki T, Maruyama D, Machida R, Kataoka T, Fukushima N, Takayama N, Ohba R, Omachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Yamamoto K, Kameoka Y, Kagami Y, Tabayashi T, Maruta M, Kobayashi T, Iida S, Nagai H. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105. Hematol Oncol. In print.（JCOG多施設共同研究）

Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci, 114(5), 2098-2108, 2023. （多施設共同研究）

Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J. Impact of treatment with anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti–SARS-CoV-2 vaccination in mature B-cell neoplasms. Infect Drug Resist, 16, 509-519, 2023.(KOTOSG研究)

Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci, 114(4), 1297-1308, 2023. （多施設共同研究）

Onishi A, Shimura Y, Nakamura T, Souri M, Osaki T, Mizutani S, Tsukamoto T, Kobayashi T, Ichonose A, Kuroda J. Management of acquired factor X deficiency caused by in vitro non-neutralizing anti-factor X autoantibodies with pre-emptive corticosteroid therapy. Intern Med, 62(16), 2401-3406, 2023.

Shimazu Y, Kanda J, Kaneko H, Imada K, Yamamura R, Kosugi S, Shimura Y, Ito T, Fuchida S, Uchiyama H, Fukushima K, Yoshihara S, Hanamoto H, Tanaka H, Uoshima N, Ohta K, Yagi H, Shibayama H, Onda Y, Tanaka Y, Adachi Y, Matsuda M, Iida M, Miyoshi T, Matsui T, Takahashi R, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J, The Kansai Myeloma Forum. Monocyte or white blood cell counts andβ2 microglobulin predict the durable efficacy of daratumumab with lenalidomide. Ther Adv Hematol, 13, 20406207221142487, 2022. （多施設共同研究）

Tsukamoto T, Kinoshita M, Yamada K, Ito H, Yamaguchi T, Chinen Y, Mizutani S, Fujino T, Kobayashi T, Shimura Y, Inazawa J, Kuroda J. Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. J Hum Genet, in print.（東京医科歯科大学、シスメックス社、BML社との共同研究）

Onishi A, Shimura Y, Nakamura T, Souri M, Osaki T, Mizutani S, Tsukamot T, Kobayashi T, Ichonose A, Kuroda J. Management of acquired factor X deficiency caused by in vitro non-neutralizing anti-factor X autoantibodies with pre-emptive corticosteroid therapy. Intern Med, in print.

Inoue Y, Hirakawa K, Hayata H, Nishiyama D, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kuroda J. Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma. Ann Hematol, 102, 481-482, 2023 (福知山市民病院との共同研究)

Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai N, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica, 108, 811-821, 2023（多施設共同研究）

Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, Uchida T, Kusumoto S, Kuroda J, Iriyama C, Yanada M, Tsukamoto N, Suehiro Y, Minami H, Garcia-Vargas J, Childs BH, Yasuda M, Masuda S, Tsujino T, Terao Y, Tobinai K. The safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study. Int J Hematol, 117, 100-109, 2023. （多施設共同研究）

Arai K, Sakaguchi M, Yui S, Kitano T, Miyata M, Yogosawa M, Nakayama K, Tajika K, Usuki K, Kuroda J, Uoshima N, Kobayashi Y, Uchiyama H, Kubota Y, Kimura S, Mori S, Hirai M, Wakita S, Yamaguchi H. Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320. Int J Lab Hematol, 44, 1102-1110, 2023. （多施設共同研究）

Mizuhara K, Kobayashi T, Nakao M, Takahashi R, Kaneko H, Shimura K, Hirakawa K, Uoshima N, Wada K, Kawata E, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Yoneda A, Watanabe A, Sotozono C, Kuroda J. Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective study. Cancer Med, 12, 3134-3144, 2023.(眼科学教室、KOTOSGの共同研究)

黒田純也. CAR-T細胞療法時代の多発性骨髄腫治療の臨床と研究の新たな課題Emerging Clinical and Research Issues in the Era of CAR-T Cell Therapy for Multiple Myeloma. 日本造血・免疫細胞療法学会雑誌 12(4), 213-221, 2023

黒田純也, 水谷信介. 多発性骨髄腫と類縁疾患. 最新のがん薬物療法2023-2024．南江堂. 226-228, 2023

黒田純也. 序文. 日本臨牀増刊号. 新リンパ腫学. 1-3, 2023

黒田純也, 岡本明也.　多発性骨髄腫におけるtreatment-freeの位置づけ. 血液内科 86(5), 656-661, 2023

黒田純也.骨髄腫進展と治療抵抗性獲得の病態. Pathophysiology and mechanisms underlying the disease progression and the acquisition of the therapeutic resistance in multiple myeloma. 日本臨牀81(6), 2023

2022

Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, Fujino T, Kataoka K, Uchida N, Eto T, Miyakoshi S, Tanaka M, Kawakita T, Yokoyama H, Doki N, Harada K, Wake A, Ota S, Takada S, Takahashi S, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanada M. Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia. 2022 Apr;36(4):1132-1138. （多施設共同研究）

Hatta S, Fukuhara S, Fujino T, Saito Y, Ito Y, Makita S, Munakata W, Suzuki T, Maruyama D, Kusumoto M, Izutsu K. The role of surveillance computed tomography in patients with follicular lymphoma. Ther Adv Hematol. 2022 May 14;13:20406207221095963.（国立がん研究センター中央病院との共同研究）

Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, Goto H, Jackson C, Sun H, Pacaud L, Fujikawa E, Yeh T, Hatayama T, Aida K, Sunagawa Y, Iida S. Ciltacabtagene. in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer Sci, 113, 4267-4276, 2022. （多施設共同研究）

Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Otsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H. Final analysis of randomized phase 2 study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci, 113, 3267-3270, 2022. （多施設共同研究）

Maekura C, Muramatsu A, Nagata H, Okamoto H, Onishi A, Kato D, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Okumura K, Inaba T, Nukui Y, Kuroda J.. Clinical implication of the effect of the production of neutralizing antibodies against SARS-Cov-2 for chronic immune thrombocytopenia flare-up associated with COVID-19 infection; a case report and the review of literature. Infect Drug Resist, 15, 2723-2728, 2022.

OndaY, Kanda J, Kaneko H, Shimura Y, Fuchida S, Nakaya A, Ito T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J, Kansai Myeloma Forum. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: A multicenter retrospective analysis. Ther Adv Hematol, 13, 20406207221104584, 2022. （多施設共同研究）

Katagiri S, Chi SG, Minami Y, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Morishita T, Kondo T, Yanada M, Yamamoto K, Kuroda J, Usuki K, Akahane D, Gotoh A. Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia. Int J Mol Sci, 23, 4694, 2022. （多施設共同研究）

Murakami S, Ri M, Ito M, Nakamura N, Kasahara S, Kitagawa J, Inagaki Y, Kuroda J, Yoshimitsu M, Okamoto A, Fukuhara N, Taji H, Iida H, Nagai H, Hanamura I, Tsujimura H, Okura M, Kurata M, Kuwatsuka Y, Atusta Y, Iida S. Efficacy anmd safety of modified BLd therapy for transplant-ineligible Japanese patients with multiple myeloma. Int J Hematol, 116, 563-659, 2022. （多施設共同研究）

Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, Chung W, Kuwayama S, Nishio M, Lee K, Iida S. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. Int J Hematol, 116, 122-130, 2022. （多施設共同研究）

Inaba T, Okumura K, Maekura C, Muramatsu A, Kobayashi T, Kuroda J, Nukui Y. Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination. Int J Hematol, 115, 916-917, 2022.

Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. Int J Hematol, 116, 199-214, 2022. （多施設共同研究）

Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The rationale for the dual targeting therapy for RSK2 and AKT in multiple myeloma. Int J Mol Sci, 23, 2919, 2022 (創薬センターとの共同研究)

Kobayashi T, Yamamoto K, Kagami Y, Machida R, Miyazaki K, Nakamura S, Kuroda J, Maruyama D, Nagai H. Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. Jpn J Clin Oncol, 52, 583-588, 2022.（多施設共同研究）

Onishi C, Nishikori M, Yakushijin K, Kurahashi S, Nakazawa H, Takamatsu Y, Hashimoto Y, Tatetsu H, Yuichiro Nawa, Yoshida M, Kobayashi T, Oyake T, Yano S, Oride A, Suzuki R. Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. Int J Hematol. 115(3), 382-390, 2022 （多施設共同研究）

Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol, 101, 979-989, 2022.（多施設共同研究）

Tomida A, Chiyonobu T, Tokuda S, Miyachi M, Murashima K, Hirata M, Nakagawa M, Iehara T, Kuroda J, Takayama K. Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant. Hum Genome Var, 8, 8, 2022.（遺伝相談室、がんゲノムセンターとの共同研究）

Fujino T, Maruyama D, Miyagi-Maesima A, Tajima K, Saito Y, Ida H, Hosoba R, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Kuroda J, Izutsu K. The outcome of watchful waiting in patients with previously treated follicular lymphoma. Cancer Med, 11, 2106-2116, 2022.（国立がん研究センターとの共同研究）

Kitaoji T, Noto Y, Kasai T, Mizuhara K, Okamoto H, Tsukamot T, Kuroda J, Mizuno T. A case of neuroleukemiosis: The usefulness of nerve ultrasound as a diagnostic tool. Muscle Nerve, 65, E19-E21, 2022.（脳神経内科との共同研究）

Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, Kuroda J, Taniwaki M. Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B- Cell Lymphoma Treated with Rituximab-Combined Chemotherapy. Int J Hematol-Oncol Stem Cell Research, 16, 1-8, 2022.

Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida S, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. Leuk Lymphoma, 11, 1-8, 2022.（KOTOSG研究）

Tsukamoto T, Tokuda Y, Nakano M, Tashiro K, Kuroda J. Expression of activated B cell gene signature is predictive of the outcome of follicular lymphoma. Blood Adv, 6, 1932-1936, 2022.（ゲノム医科学との共同研究）

Matsumoto Y, Ayani N, Omichi C, Oya N, Matsuoka T, Kobayashi T, Kuroda J, Narumoto J. Diagnostic error about the cause of cytopenia during increasing psychotropic drugs: two case reports. Asian J Psychiatr, 67; 102952, 2022. (精神科との共同研究)

Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. Int J Hematol, 115, 350-362, 2022.（KOTOSG研究）

Taminishi-Katsuragawa Y, Shimura Y, Inoue Y, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Kobayashi T, Takeda-Miyata N, Nishimura A, Takatsuka K, Kuroda J. Gastric myeloid sarcoma mimicking a scirrhous gastric cancer. Intern Med, 61:1231-1235, 2022.

2021

Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Very low-dose dasatinib in elderly chronic myeloid leukaemia patients (DAVLEC study): a single-arm, multicentre, phase 2 trial. Lancet Haematol, 8, e902-e911, 2021.（多施設共同研究）

Takahashi T, Suzuki R, Yamamoto G, Nakazawa H, Kurosawa M, Kobayashi T, Okada M, Akasaka T, Kim SW, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan. Hematol Oncol. 39, 66-74, 2021多施設共同研究）

Nakaya A, Shibayama H, Naklatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida S, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicventer retrospective analysis in Kansai Myeloma Forum. eJHaem, 1-9, 2021. （多施設共同研究）

Okamoto H, Uoshima N, Muramatsu A, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Kawata E, Uchiyama H, Kuroda J, Kyoto Clinical Hematology Study Group investigators* Combination of bone marrow biopsy and flow cytometric analysis: The prognostically relevant central approach for detecting bone marrow invasion in diffuse large B-cell lymphoma. Diagnostics, 11:1724, 2021.（KOTOSG研究）

Nagata H, Kuriyama K, Nishikawa R, Ohshiro M, Yamamoto-Sugitani M, Fujimoto-Hirakawa Y, Matsumoto Y, Iwai T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Fukuda W, Uchiyama H, Kuroda J. Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder. Ann Hematol, 100, 2849-2850, 2021.

Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Int J Clin Oncol, 26:2131-2141, 2021. （多施設共同研究）

Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Jpn J Clin Oncol, 51:1372-1382, 2021. （多施設共同研究）

Yamashita T, Takamatsu H, Kawamura K, Sunami K, Hagiwara S, Epid GDC, Itagaki M, MD, Takahashi T, Kondo K, Ikeda T, Watakabe-Inamoto K, Handa H, Imaizumi Y, Kuroda J, Murakami J, Nakamura Y, Nakazawa H, Ozaki S, Ohkura M, Takeuchi M, MD, Nagai H, Hanamura I, Nakao S, Tobinai K, Iida S. A nationwide survey on central nervous system multiple myeloma in Japan: Analysis of prognostic factors that improve survival. Br J Haematol, 195:217-229, 2021. （多施設共同研究）

Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Hojo S, Nakanishi T, Rai S. Phase 2 Study of Tazemetostat for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma with EZH2 Mutation in Japan. Cancer Sci, 112:3627-3635, 2021. （多施設共同研究）

Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida S, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Reports, e1476, 2021.（KOTOSG研究）

Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Kizaki M, Negoro E, Handa H, Iida S. Expression of activated integrin β7 in multiple myeloma patients. Int J Hematol, 114(1); 3-7, 2021. （多施設共同研究）

Katsuragawa-Taminishi Y, Ide D, Maegawa-Matsui S, Fuchida S, Hatsuse M, Murakami S, Kuroda J, Shimazaki C. Acquired Amegakaryocytic Thrombocytopenic Purpura that Presented as Cyclic Thrombocytopenia Associated with Anti-Phospholipid Antibody Syndrome. Clin Hematol Res, 4(1), 42-46, 2021.

Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci, 112(7): 2845-2854, 2021（多施設共同研究）

Okamoto H, Kamitsuji Y, Komori Y, Sasaki N, Tsutsumi Y, Miyashita A, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Uoshima N, Kuroda J. Durable remission of chemotherapy-refractory myeloid sarcoma by azacitidine. Tohoku J Exp Med, 254(2); 101-105, 2021.

Matsumoto Y, Tsukamoto T, Chinen Y, Shimura Y, Sasaki N, Nagoshi H, Sato R, Adachi H, Nakano M, Horiike S, Kuroda J, Taki T, Tashiro K, Taniwaki M. Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma. J Clin Exp Hematop, 61(2); 71-77, 2021.

Wakita S, Sakaguchi M, Oh, Kako S, Touya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y、Shono K, Shibusawa M、Tadokoro J、Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Myata M, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv,6(1); 238-247, 2022. （多施設共同研究）

Kawai H, Ando K, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, Kato K, Nakanishi T, Nakai K, Matsunaga R, Tobinai K. Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci, 112(6); 2426-2435, 2021. （多施設共同研究）

Matsumoto M, Suzuki K, Kuroda J, Taniwaki M, Sunami K, Kosugi H, Ando K, Maruyama D, Tobinai K, Kher U, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Iida S. Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients. Int J Hematol, 113(6); 777-784, 2021. （多施設共同研究）

Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida S, Shimura Y, Yagi H, Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I. Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. Hematol Oncol, 39(3):349-357, 2021（多施設共同研究）

Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida S, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Real-world outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis from Kansai Myeloma Forum. Eur J Haematol, 106: 555-562, 2021（多施設共同研究）

Okamoto H, Uoshima N, Kamitsuji Y, Kawata E, Komori Y, Sasaki N, Tsutsumi Y, Tsukamoto T, Mizutani S, Nannya Y, Kuroda J. Paroxysmal Nocturnal Hemoglobinuria Complicated with Essential Thrombocythemia Harboring Concomitant PIGA, CALR And ASXL1 Mutations. Ann Hematol, 100(8):2113-2115, 2021 (KOTOSG関連報告)

Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H. A randomized phase II/III study of R-CHOP versus CHOP combined with dose-dense rituximab for DLBCL: JCOG0601. Blood Adv, 5: 984-993, 2021.（多施設共同研究）

Yasuda T, Takagi T, Asai J, Katoh N, Kuroda J, Kuwahara Y, Morionaga Y, Konishi E, Uchiyama K, Naito Y, Itoh Y. Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. Clin J Gastroenterol, 14: 170-175, 2021.（本学消化器内科学との共同研究）

Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Ts Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. Int J Hematol, 113: 381-394, 2021.（群馬大学血液内科との共同研究）

Maruyama D, Iida S, Ogawa G, Kusumoto S, Fukuhara S, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Tokunaga T, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Miyamoto K, Watanabe Y, Tobinai K, Tsukasaki K, Nagai H. Randomized phase II study to optimize melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol, 192: 531-541, 2021.（多施設共同研究）

Kanai R, Miyagawa-Hayashino A, Shishido-Hara Y, Nakamura N, Omatsu I, Morinaga Y, Shimura Y, Kuroda J, Itoh K, Konishi E. Mantle cell lymphoma with EBV-positive Hodgkin and Reed-Sternberg-like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors. Pathol Int, 71: 96-101, 2021.（本学病院病理部との共同研究）

研　究

業　績

KOTOSG

業績

2025

2024

2023

2022

2021

研 究

研　究